entry inhibitors


Also found in: Wikipedia.

entry inhibitors

A new class of drugs that are designed to block entry of viruses into cells. Viral receptors to which viruses bind have a critical role in entry. They mediate fusion between the viral and the cell membranes. Some inhibitors bind to these receptors. Others bind to the viruses and prevent interaction with the receptors. A third class inhibit the conformational changes necessary for cell and virus membrane fusion.
References in periodicals archive ?
PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
In order to efficiently block intracellular fusion events, the next generation of HIV entry inhibitors must be able to permeate the cell membrane," he added.
5 (intermediate 0 (low penetration) penetration) Nucleoside or nucleotide reverse transcriptase inhibitors Retrovir (zidovudine) Emtriva Videx (didanosine) (emtricitabine) Ziagen (abacavir) Epivir (lamivudine) Viread (tenofovir) Zerit (stavudine) Nonnucleoside reverse transcriptase inhibitors Viramune (nevirapine) Sustiva (efavirenz) Intelence (etravirine) * Protease inhibitors Crixivan (indinavir) Reyataz (atazanavir) Aptivus (tipranavir) + (+ RTV) RTV Kaletra (lopinavir + Reyataz + RTV Invirase (saquinavir) RTV) + RTV Agenerase[dagger] Prezista (darunavir) + Norvir (ritonavir) (amprenavir) + RTV RTV Viracept (nelfinavir) Entry inhibitors Selzentry Fuzeon (enfuvirtide) (maraviroc) * Integrase inhibitors Isentress (raltegravir) * RTV = ritonavir (Norvir).
Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
Mitsuya also made a direct contribution to advancing research and development into entry inhibitors and the clinical implementation of
All the other products mentioned are called HIV entry inhibitors and block HIV infection.
SAN FRANCISCO -- Efforts to develop entry inhibitors, which constitute the first new class of anti-HIV drugs in years, have hit snags that could delay the entry of these novel agents into the pharmaceutical marketplace.
Three CCR5 entry inhibitors have recently been in large clinical trials: aplaviroc from GlaxoSmithKline, maraviroc from Pfizer, and vicriviroc from Schering Plough.
Entry inhibitors gain attention as a potential new class of antiretrovirals.
In addition, newer agents with novel mechanisms of action, such as HIV entry inhibitors (which inhibit the three steps of HIV entry: CD4 attachment, chemokine co-receptor binding and membrane fusion) and HIV integrase inhibitors, are also under investigation.
Entry inhibitors work in various ways to block HIV before it takes over the cell, either on the virus itself or on the cell.